Combination therapy in idiopathic pulmonary fibrosis: The way ahead will be hard

European Respiratory Journal

Volumn 45, Issue 5, 2015, Pages 1208-1210

  Wells, Athol ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NINTEDANIB; PIRFENIDONE; PLACEBO; INDOLE DERIVATIVE; PYRIDONE DERIVATIVE;

AREA UNDER THE CURVE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG ACCUMULATION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; GASTROINTESTINAL DISEASE; HOSPITALIZATION; HUMAN; LUNG CANCER; MAXIMUM PLASMA CONCENTRATION; MORTALITY; NON SMALL CELL LUNG CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SMALL CELL LUNG CANCER; TREATMENT DURATION; TREATMENT OUTCOME; FEMALE; IDIOPATHIC PULMONARY FIBROSIS; MALE;

FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INDOLES; MALE; PYRIDONES;

EID: 84929012573     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00043915     Document Type: Review

References (15)

1. Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010; 35: 821-829.
2. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): Two randomised trials. Lancet 2011; 377: 1760-1769.
3. Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011; 365: 1079-1087.
4. King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2083-2092.
5. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2071-2082.
6. Wuyts WA, Antoniou KM, Borensztajn K, et al. Combination therapy: The future of management for idiopathic pulmonary fibrosis? Lancet Respir Med 2014; 2: 933-942.
7. Ogura T, Taniguchi H, Azuma A, et al. Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2015; 45: 1382-1392.
8. Ley B, Bradford WZ, Weycker D, et al. Unified baseline and longitudinal mortality prediction in idiopathic pulmonary fibrosis. Eur Respir J 2015; 45: 1374-1381.
9. Ley B, Ryerson CJ, Vittinghoff E, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 2012; 156: 684-691.
10. Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013; 188: 733-748.
11. King TE Jr, Albera C, Bradford WZ, et al. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): A multicentre, randomised, placebo-controlled trial. Lancet 2009; 374: 222-228.
12. du Bois RM, Weycker D, Albera C, et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 184: 459-466.
13. Foster NR, Qi Y, Shi Q, et al. Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials. Cancer 2011; 117: 1262-1271.
14. Li X, Liu S, Gu H, et al. Surrogate end points for survival in the target treatment of advanced non-small-cell lung cancer with gefitinib or erlotinib. J Cancer Res Clin Oncol 2012; 138: 1963-1969.
15. Fleming TR, Rothmann MD, Lu HL. Issues in progression-free survival when evaluating oncology products. J Clin Oncol 2009; 27: 2874-2880.